SEP 2, 2026 · JOURNAL ARTICLE
Safety of immune checkpoint inhibitor rechallenge and mid-term outcomes after suspected cardiovascular immune-related adverse events
Cardio-oncology
A prospective single-centre cohort study with adjudicated endpoints and identified predictors of mid-term CV events, but limited by single-centre design and lack of a comparator arm, providing real results that require confirmation in larger populations.
Reported
Sample size175
Median age (IQR)61 years (48–72)
Adjudicated CV irAEs95 (54.3%)